{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:55Z","timestamp":1786991875841,"version":"build-2736575974"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jconrel.2023.09.021","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T17:54:22Z","timestamp":1696442062000},"page":"464-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration"],"prefix":"10.1016","volume":"363","author":[{"given":"Eduardo A.","family":"Chacin Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn E.","family":"Swindle-Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlee N.","family":"Ford Versypt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.09.021_bb0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2014.05.031","article-title":"Nanotherapy for posterior eye diseases","volume":"193","author":"Kaur","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vision"},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archophthalmol.2009.58","article-title":"Forecasting age-related macular degeneration through the year 2050. the potential impact of new treatments","volume":"127","author":"Rein","year":"2009","journal-title":"Arch. Ophthalmol."},{"issue":"11","key":"10.1016\/j.jconrel.2023.09.021_bb0020","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull. W. H. O."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0025","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajo.2011.05.008","article-title":"Medicare costs for neovascular age-related macular degeneration, 1994\u20132007","volume":"152","author":"Day","year":"2011","journal-title":"Am J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13036-022-00291-y","article-title":"Tissue engineering in age-related macular degeneration: a mini-review","volume":"16","author":"Wu","year":"2022","journal-title":"J. Biol. Eng."},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2040622312446007","article-title":"Aflibercept in wet age-related macular degeneration: a perspective review","volume":"3","author":"Ohr","year":"2012","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000517520","article-title":"Age-related macular degeneration: pathophysiology, management, and future perspectives","volume":"244","author":"Flores","year":"2021","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0045","first-page":"133","article-title":"Triple therapy for choroidal neovascularization due to agerelated macular degeneration - verteporfin PDT, bevacimmab, and dexamethasone","volume":"27","author":"Augustin","year":"2007","journal-title":"Retina- J. Retinal Vitreous Dis."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0050","first-page":"74","article-title":"Age-related macular degeneration","volume":"59","author":"Gheorghe","year":"2015","journal-title":"Rom. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0039-6257(88)90052-5","article-title":"Age-related macular degeneration","volume":"32","author":"Bressler","year":"1988","journal-title":"Surv. Ophthalmol."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0065","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clinbiochem.2005.11.013","article-title":"Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions","volume":"39","author":"Tong","year":"2006","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0075","series-title":"Retinal Pharmacotherapeutics","first-page":"28","article-title":"Ocular angiogenesis: vascular endothelial growth factor and other factors","author":"Rubio","year":"2016"},{"issue":"9827","key":"10.1016\/j.jconrel.2023.09.021_bb0080","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0085","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2174\/0929867326666190726121711","article-title":"Pharmacological advances in the treatment of age-related macular degeneration","volume":"27","author":"Gil-Martinez","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14656566.2022.2154145","article-title":"The state-of-the-art pharmacotherapeutic management of neovascular age-related macular degeneration","volume":"24","author":"Servillo","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0095","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.drudis.2022.04.013","article-title":"Novel and investigational therapies for wet and dry age-related macular","volume":"27","author":"Sarkar","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.jconrel.2023.09.021_bb0100","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/biom12111629","article-title":"Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration","volume":"12","author":"ElSheikh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","article-title":"The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis","volume":"192","author":"Okada","year":"2018","journal-title":"Am J. Ophthalmol."},{"issue":"24","key":"10.1016\/j.jconrel.2023.09.021_bb0110","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/molecules27248828","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fernandez","year":"2020","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135608","article-title":"Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of anti-VEGF therapies","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0125","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1038\/s41598-017-03959-4","article-title":"A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles","volume":"7","author":"Sousa","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1248\/bpb.b16-00437","article-title":"Development of a sustainable release system for a ranibizumab biosimilar using poly(lactic-co-glycolic acid) biodegradable polymer-based microparticles as a platform","volume":"40","author":"Tanetsugu","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0135","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res., Part A"},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0140","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","article-title":"Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles","volume":"11","author":"Tsujinaka","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0145","doi-asserted-by":"crossref","first-page":"8819","DOI":"10.2147\/IJN.S217038","article-title":"Anti-angiogenic activity of bevacizumab-bearing dexamethasone-loaded PLGA nanoparticles for potential intravitreal applications","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.10.026","article-title":"Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model","volume":"244","author":"Adamson","year":"2016","journal-title":"J. Control. Release"},{"issue":"33","key":"10.1016\/j.jconrel.2023.09.021_bb0155","doi-asserted-by":"crossref","first-page":"17298","DOI":"10.1039\/D0NR03710A","article-title":"Controlled release of anti-VEGF by redox-responsive polydopamine nanoparticles","volume":"12","author":"Jiang","year":"2020","journal-title":"Nanoscale"},{"issue":"7","key":"10.1016\/j.jconrel.2023.09.021_bb0160","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acs.molpharmaceut.0c00260","article-title":"Chitosan-polycaprolactone core-shell microparticles for sustained delivery of bevacizumab","volume":"17","author":"Jiang","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejpb.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study","volume":"4","author":"Yu","year":"2015","journal-title":"Transl. Vision Sci. Technol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13346-018-0520-x","article-title":"Freeze-dried matrices for ocular administration of bevacizumab: comparison between subconjunctival and intravitreal administration in rabbits","volume":"8","author":"Burgalassi","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0180","doi-asserted-by":"crossref","first-page":"632","DOI":"10.34172\/apb.2021.072","article-title":"A novel approach for development of intraocular biodegradable ranibizumab implant: a solution for stability of protein activity","volume":"11","author":"Pakdel","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0185","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jconrel.2020.01.036","article-title":"Injectable biodegradable bi-layered capsule for sustained delivery of bevacizumab in treating wet age-related macular degeneration","volume":"320","author":"Jiang","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics15010243","article-title":"Fabrication and characterisation of 3D-printed triamcinolone acetonide-loaded polycaprolactone-based ocular implants","volume":"15","author":"Annuryanti","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11095-017-2298-9","article-title":"Synthesis and characterisation of photocrosslinked poly(ethylene glycol) diacrylate implants for sustained ocular drug delivery","volume":"35","author":"McAvoy","year":"2018","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0200","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/polym13040642","article-title":"Nanoparticle-hydrogel composite drug delivery system for potential ocular applications","volume":"13","author":"Hsu","year":"2021","journal-title":"Polymers"},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0205","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbm.a.36424","article-title":"Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment","volume":"106","author":"Badiee","year":"2018","journal-title":"J. Biomed. Mater. Res., Part A"},{"issue":"30","key":"10.1016\/j.jconrel.2023.09.021_bb0210","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1016\/j.biomaterials.2013.06.044","article-title":"Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide","volume":"34","author":"Shmueli","year":"2013","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0215","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.jconrel.2023.09.021_bb0220","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.molpharmaceut.6b00335","article-title":"PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab","volume":"13","author":"Elsaid","year":"2016","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0225","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.10","article-title":"Modeling of drug release from polymeric delivery systems\u2013a review","volume":"21","author":"Kanjickal","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"11","key":"10.1016\/j.jconrel.2023.09.021_bb0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11095-018-2498-y","article-title":"Targeted ocular drug delivery with pharmacokinetic\/pharmacodynamic considerations","volume":"35","author":"Shen","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0240","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.preteyeres.2010.04.001","article-title":"Protein delivery for retinal diseases: from basic considerations to clinical applications","volume":"29","author":"El Sanharawi","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0245","first-page":"348","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"Am. Assoc. Pharm. Sci. J."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0250","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acs.molpharmaceut.0c00224","article-title":"Nanoparticulate drug delivery to the retina","volume":"18","author":"Li","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0255","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2021.121105","article-title":"Recent advances in ophthalmic preparations: ocular barriers, dosage forms and routes of administration","volume":"608","author":"Maulvi","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1872211308666140130093301","article-title":"Drug delivery to the back of the eye following topical administration: an update on research and patenting activity","volume":"8","author":"Boddu","year":"2014","journal-title":"Recent Pat. Drug Delivery Formul."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0265","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1600-0420.2007.00885.x","article-title":"Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye","volume":"85","author":"Sigurdsson","year":"2007","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0270","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic side effects of eye drops: a pharmacokinetic perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0275","doi-asserted-by":"crossref","first-page":"787644","DOI":"10.3389\/fmed.2021.787644","article-title":"Considerations for polymers used in ocular drug delivery","volume":"8","author":"Allyn","year":"2022","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0280","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1167\/iovs.11-7525","article-title":"Effect and distribution of contrast medium after injection into the anterior suprachoroidal space in ex vivo eyes","volume":"52","author":"Seiler","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0285","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.drudis.2014.10.010","article-title":"The suprachoroidal pathway: a new drug delivery route to the back of the eye","volume":"20","author":"Rai","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0290","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/OPTH.S89784","article-title":"The suprachoroidal space: from potential space to a space with potential","volume":"10","author":"Moisseiev","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0300","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/17425247.1.1.99","article-title":"Periocular routes for retinal drug delivery","volume":"1","author":"Raghava","year":"2004","journal-title":"Expert. Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0305","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/10807680152729257","article-title":"Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection","volume":"17","author":"Lee","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"5\u20136","key":"10.1016\/j.jconrel.2023.09.021_bb0310","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2010.12.004","article-title":"Drug delivery to the posterior segment of the eye","volume":"16","author":"Thrimawithana","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0315","first-page":"1038","article-title":"Nanotechnology in retinal drug delivery","volume":"11","author":"Jiang","year":"2018","journal-title":"Int. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0320","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0325","series-title":"Pharmacologic Therapy of Ocular Disease","first-page":"57","article-title":"Ocular drug delivery","author":"Yavuz","year":"2017"},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0330","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0335","first-page":"1847","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab, retina","volume":"37","author":"Avery","year":"2017","journal-title":"J. Retinal Vitreous Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0340","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","article-title":"Complications of intravitreal injections","volume":"21","author":"Sampat","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"7","key":"10.1016\/j.jconrel.2023.09.021_bb0345","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye"},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0350","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/acs.biomac.1c00160","article-title":"Sustained release systems for delivery of therapeutic peptide\/protein","volume":"22","author":"Nie","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpharm.2019.118767","article-title":"Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration","volume":"573","author":"Luaces-Rodriguez","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0360","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jconrel.2020.09.020","article-title":"Zero-order drug delivery: state of the art and future prospects","volume":"327","author":"Laracuente","year":"2020","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0365","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/jps.21987","article-title":"A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases","volume":"99","author":"Choonara","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0370","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2015.09.065","article-title":"Delivery strategies for treatment of age-related ocular diseases: from a biological understanding to biomaterial solutions","volume":"219","author":"Delplace","year":"2015","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0375","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/prp2.723","article-title":"Biological drug therapy for ocular angiogenesis: anti-VEGF agents and novel strategies based on nanotechnology","volume":"9","author":"Formica","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0380","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0385","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.preteyeres.2014.04.002","article-title":"The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies","volume":"42","author":"Herrero-Vanrell","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0390","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/nnm-2016-0379","article-title":"Drug delivery to the eye: what benefits do nanocarriers offer?","volume":"12","author":"Joseph","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0395","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.addr.2018.03.013","article-title":"Controlled release technology for anti-angiogenesis treatment of posterior eye diseases: current status and challenges","volume":"126","author":"Lau","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0400","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0405","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery","volume":"13","author":"Sahoo","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0410","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1389450053765914","article-title":"Colloidal carriers for ophthalmic drug delivery","volume":"6","author":"Mainardes","year":"2005","journal-title":"Curr. Drug Targets"},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0415","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.drudis.2019.05.032","article-title":"The safety evaluation of long-acting ocular delivery systems","volume":"24","author":"Thackaberry","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0420","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/17425247.2016.1227783","article-title":"Recent perspectives on the delivery of biologics to back of the eye","volume":"14","author":"Joseph","year":"2017","journal-title":"Expert. Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0425","first-page":"961","article-title":"Drug delivery for posterior segment eye disease","volume":"41","author":"Geroski","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0430","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1023\/A:1015841715384","article-title":"Controlled delivery systems for proteins based on poly(lactic\/glycolic acid) microspheres","volume":"8","author":"Cohen","year":"1991","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0435","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0440","series-title":"Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (ALTISSIMO), Clinical Trial NCT03953079. Updated Jan 19","volume":"2022","author":"Depot","year":"2022"},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0445","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1039\/c1nr10969c","article-title":"Polydopamine-a nature-inspired polymer coating for biomedical science","volume":"3","author":"Lynge","year":"2011","journal-title":"Nanoscale"},{"issue":"9","key":"10.1016\/j.jconrel.2023.09.021_bb0450","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.biomaterials.2005.09.019","article-title":"The in vivo degradation, absorption and excretion of PCL-based implant","volume":"27","author":"Sun","year":"2006","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0455","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0142-9612(01)00094-1","article-title":"In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant","volume":"23","author":"Mi","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0460","first-page":"7","article-title":"Hydrogels as drug delivery systems; pros and cons","volume":"5","author":"Ghasemiyeh","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0465","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/17425247.2017.1272569","article-title":"How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches","volume":"14","author":"Agrahari","year":"2017","journal-title":"Expert. Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0470","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2012.10.015","article-title":"Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres\u2013a review","volume":"165","author":"Ford Versypt","year":"2013","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0480","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejps.2009.07.007","article-title":"Application of dynamic neural networks in the modeling of drug release from polyethylene oxide matrix tablets","volume":"38","author":"Petrovic","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.09.021_bb0485","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2012.02.031","article-title":"Optimization of matrix tablets controlled drug release using elman dynamic neural networks and decision trees","volume":"428","author":"Petrovic","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0490","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41467-022-35343-w","article-title":"Machine learning models to accelerate the design of polymeric long-acting injectables","volume":"14","author":"Bannigan","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0495","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/17425247.2014.924497","article-title":"Application of mathematical modeling in sustained release delivery systems","volume":"11","author":"Grassi","year":"2014","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0500","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trac.2017.12.008","article-title":"Engineering design and mechanistic mathematical models: standpoint on cutting edge drug delivery","volume":"100","author":"Parmar","year":"2017","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0505","series-title":"Encapsulation of Active Molecules and their Delivery System","first-page":"257","article-title":"Mathematical modeling and simulation of the release of active agents from nanocontainers\/microspheres","author":"Pradhane","year":"2020"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2023.09.021_bb0510","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(01)00116-8","article-title":"Mathematical modeling of bioerodible, polymeric drug delivery systems","volume":"48","author":"Siepmann","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0515","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijpharm.2008.09.004","article-title":"Mathematical modeling of drug delivery","volume":"364","author":"Siepmann","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0520","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jconrel.2011.10.006","article-title":"Modeling of diffusion controlled drug delivery","volume":"161","author":"Siepmann","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0525","first-page":"153","article-title":"Swelling controlled drug delivery systems","author":"Siepmann","year":"2012","journal-title":"Adva. Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0530","series-title":"Controlled Release of Biologically Active Agents","author":"Baker","year":"1987"},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0535","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jps.2600590317","article-title":"Release of medroxyprogesterone acetate from a silicone polymer","volume":"59","author":"Roseman","year":"1970","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0540","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jps.2600610106","article-title":"Release of steroids from a silicone polymer","volume":"61","author":"Roseman","year":"1972","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0545","series-title":"The Mathematics of Diffusion","author":"Crank","year":"1975"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0550","series-title":"Controlled Drug Release of Oral Dosage Forms","author":"Vergnaud","year":"1993"},{"issue":"17","key":"10.1016\/j.jconrel.2023.09.021_bb0555","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/mma.3007","article-title":"Mathematical modeling of drug delivery from cylindrical implantable devices","volume":"37","author":"Ibarra","year":"2014","journal-title":"Math. Meth. Appl. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0560","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0168-3659(93)90037-6","article-title":"Mathematical analysis of drug release from a coated particle","volume":"23","author":"Lu","year":"1993","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0565","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.msec.2014.06.009","article-title":"Analytical and numerical study of diffusion-controlled drug release from composite spherical matrices","volume":"42","author":"Hadjitheodorou","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0570","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.compbiomed.2017.12.010","article-title":"Mechanistic modelling of drug release from multi-layer capsules","volume":"93","author":"Kaoui","year":"2018","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mbs.2018.04.004","article-title":"Modelling mass diffusion for a multi-layer sphere immersed in a semi-infinite medium: application to drug delivery","volume":"303","author":"Carr","year":"2018","journal-title":"Math. Biosci."},{"issue":"9","key":"10.1016\/j.jconrel.2023.09.021_bb0580","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.xphs.2018.04.024","article-title":"Design of hollow hyaluronic acid cylinders for sustained intravitreal protein delivery","volume":"107","author":"Van Kampen","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0585","series-title":"Dynamically Swelling Hydrogels in Controlled Release Applications","first-page":"109","author":"Peppas","year":"1986"},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0590","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0378-5173(89)90306-2","article-title":"A simple equation for the description of solute release. III. Coupling of diffusion and relaxation","volume":"57","author":"Peppas","year":"1989","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0595","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/js960307p","article-title":"Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics","volume":"86","author":"Kim","year":"1997","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0600","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0376-7388(00)80471-8","article-title":"Modeling of drug diffusion through swellable polymeric systems","volume":"7","author":"Peppas","year":"1980","journal-title":"J. Membr. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0605","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/jps.2600841213","article-title":"Drug-release from hydrophylic matrices. 1. New scaling laws for predicting polymer and drug-release based on the polymer disentanglement concentration and the diffusion layer","volume":"84","author":"Ju","year":"1995","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0610","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/jps.2600841214","article-title":"Drug-release from hydrophilic matrices. 2. A mathematical-model based on the polymer disentanglement concentration and the diffusion layer","volume":"84","author":"Ju","year":"1995","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0615","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1021\/js9802291","article-title":"A new model describing the swelling and drug release kinetics from hydroxypropyl methylcellulose tablets","volume":"88","author":"Siepmann","year":"1999","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0620","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1023\/A:1026455822595","article-title":"Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the \u201csequential layer\u201d model)","volume":"17","author":"Siepmann","year":"2000","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0625","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2006.05.004","article-title":"A model for the drug release from a polymer matrix tablet - effects of swelling and dissolution","volume":"113","author":"Borgquist","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0630","series-title":"Vol. 33 of ACS Symposium Series","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/bk-1976-0033.ch003","article-title":"Controlled release from erodible slabs, cylinders, and spheres","author":"Hopfenberg","year":"1976"},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0635","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/aic.690180234","article-title":"Effect of geometry on the dissolution of pharmaceutical tablets and other solids: surface detachment kinetics controlling","volume":"18","author":"Cooney","year":"1972","journal-title":"AICHE J."},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0640","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/0009-2509(90)80116-V","article-title":"Development and temporal evolution of erosion fronts in bioerodible controlled release devices","volume":"45","author":"Zygourakis","year":"1990","journal-title":"Chem. Eng. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0645","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0142-9612(96)85757-7","article-title":"Computer-aided design of bioerodible devices with optimal release characteristics: a cellular automata approach","volume":"17","author":"Zygourakis","year":"1996","journal-title":"Biomaterials"},{"issue":"16","key":"10.1016\/j.jconrel.2023.09.021_bb0650","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1021\/ma00068a006","article-title":"Modeling of polymer erosion","volume":"26","author":"Gopferich","year":"1993","journal-title":"Macromolecules"},{"issue":"9","key":"10.1016\/j.jconrel.2023.09.021_bb0655","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1021\/ma961627y","article-title":"Polymer bulk erosion","volume":"30","author":"Gopferich","year":"1997","journal-title":"Macromolecules"},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0660","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0168-3659(94)00064-2","article-title":"Modeling monomer release from bioerodible polymers","volume":"33","author":"Gopferich","year":"1995","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0665","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1023\/A:1021457911533","article-title":"A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations","volume":"19","author":"Siepmann","year":"2002","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0670","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/jps.10463","article-title":"Simulation of drug release from biodegradable polymeric microspheres with bulk and surface erosions","volume":"92","author":"Zhang","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0675","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jconrel.2022.09.067","article-title":"A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles","volume":"351","author":"Stiepel","year":"2022","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0680","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00161-021-01046-8","article-title":"A holistic continuum model-based approach to drug release","volume":"34","author":"Morozova","year":"2022","journal-title":"Contin. Mech. Thermodyn."},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0685","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1021\/js9604117","article-title":"A theoretical model of erosion and macromolecular drug release from biodegrading microspheres","volume":"86","author":"Batycky","year":"1997","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0690","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0928-0987(02)00023-4","article-title":"PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release","volume":"15","author":"Faisant","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0695","series-title":"21st European Symposium on Computer Aided Process Engineering (ESCAPE-21), Vol. 29 of Computer-Aided Chemical Engineering","first-page":"1475","article-title":"Multi-scale modeling of PLGA microparticle drug delivery systems","author":"Ford","year":"2011"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0700","series-title":"Modeling of Controlled-Release Drug Delivery from Autocatalytically Degrading Polymer Microspheres","author":"Versypt","year":"2012"},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135506","article-title":"Derivation of an analytical solution to a reaction-diffusion model for autocatalytic degradation and erosion in polymer microspheres","volume":"10","author":"Ford Versypt","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0710","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1021\/acs.molpharmaceut.6b00313","article-title":"A mechanistic model for acidic drug release using microspheres made of PLGA 50:50","volume":"13","author":"Sevim","year":"2016","journal-title":"Mol. Pharm."},{"issue":"46","key":"10.1016\/j.jconrel.2023.09.021_bb0715","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.2174\/1381612822666160923120244","article-title":"Predictive modeling of ocular pharmacokinetics and adverse effects","volume":"22","author":"Ghemtio","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0720","doi-asserted-by":"crossref","DOI":"10.1115\/1.4042297","article-title":"Diffusive transport in the vitreous humor: experimental and analytical studies","volume":"141","author":"Penkova","year":"2019","journal-title":"J. Heat Transf."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0725","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11095-012-0847-9","article-title":"Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment","volume":"30","author":"Haghjou","year":"2013","journal-title":"Pharm. Res."},{"issue":"11","key":"10.1016\/j.jconrel.2023.09.021_bb0730","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11095-020-02946-1","article-title":"Extended pharmacokinetic model of the intravitreal injections of macromolecules in rabbits. Part 2: parameter estimation based on concentration dynamics in the vitreous, retina, and aqueous humor","volume":"37","author":"Lamminsalo","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0735","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijheatmasstransfer.2013.11.002","article-title":"A technique for drug surrogate diffusion coefficient measurement by intravitreal injection","volume":"70","author":"Penkova","year":"2014","journal-title":"Int. J. Heat Mass Transf."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0740","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1615\/JPorMedia.2020028229","article-title":"Measurement of the hydraulic conductivity of the vitreous humor","volume":"23","author":"Penkova","year":"2020","journal-title":"J. Porous Media"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0745","doi-asserted-by":"crossref","first-page":"012024","DOI":"10.1088\/1757-899X\/297\/1\/012024","article-title":"Mass diffusion coefficient measurement for vitreous humor using FEM and MRI","volume":"297","author":"Rattanakijsuntorn","year":"2018","journal-title":"IOP Conf. Ser.: Mater. Sci. Eng."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0750","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1023\/A:1007517912927","article-title":"Permeability and diffusion in vitreous humor: implications for drug delivery","volume":"17","author":"Xu","year":"2000","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0755","doi-asserted-by":"crossref","DOI":"10.1115\/1.4049033","article-title":"In vivo experimental and analytical studies for bevacizumab diffusion coefficient measurement in the rabbit vitreous humor","volume":"143","author":"Zhang","year":"2021","journal-title":"J. Heat Transf."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0760","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11095-010-0356-7","article-title":"Contribution of saccadic motion to intravitreal drug transport: theoretical analysis","volume":"28","author":"Balachandran","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0765","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.medengphy.2020.06.005","article-title":"A drug delivery analysis of large molecules in ocular vitreous chamber: dependency on saccadic movements after intravitreal injection","volume":"82","author":"Ferroni","year":"2020","journal-title":"Med. Eng. Phys."},{"issue":"9","key":"10.1016\/j.jconrel.2023.09.021_bb0770","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1021\/acs.molpharmaceut.5b00849","article-title":"A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration","volume":"13","author":"Hutton-Smith","year":"2016","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0775","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","article-title":"Ocular pharmacokinetics of therapeutic antibodies given by intravitreal injection: estimation of retinal permeabilities using a 3-compartment semi-mechanistic model","volume":"14","author":"Hutton-Smith","year":"2017","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2023.09.021_bb0780","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1021\/acs.molpharmaceut.8b00280","article-title":"Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic\/pharmacodynamic model","volume":"15","author":"Hutton-Smith","year":"2018","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0785","doi-asserted-by":"crossref","DOI":"10.1115\/1.4053197","article-title":"Mathematical model of macromolecular drug transport in a partially liquefied vitreous humor","volume":"144","author":"Khoobyar","year":"2022","journal-title":"J. Heat Transf."},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0790","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11095-018-2435-0","article-title":"Extended pharmacokinetic model of the rabbit eye for intravitreal and intracameral injections of macromolecules: quantitative analysis of anterior and posterior elimination pathways","volume":"35","author":"Lamminsalo","year":"2018","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0795","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","article-title":"Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes","volume":"29","author":"Missel","year":"2012","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2023.09.021_bb0800","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10237-012-0398-3","article-title":"Saccade movements effect on the intravitreal drug delivery in vitreous substitutes: a numerical study","volume":"12","author":"Modareszadeh","year":"2013","journal-title":"Biomech. Model. Mechanobiol."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0805","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular pharmacokinetics of intravitreal aflibercept (eylea) in a rabbit model","volume":"57","author":"Park","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0810","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1167\/iovs.17-23632","article-title":"Three-dimensional transport model for intravitreal and suprachoroidal drug injection","volume":"59","author":"Zhang","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.021_bb0815","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s13346-020-00878-2","article-title":"Computational modeling of intraocular drug delivery supplied by porous implants","volume":"11","author":"Abootorabi","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"11","key":"10.1016\/j.jconrel.2023.09.021_bb0820","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s11095-008-9691-3","article-title":"Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow","volume":"25","author":"Balachandran","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0825","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13362-016-0031-7","article-title":"Mathematical assessment of drug build-up in the posterior eye following transscleral delivery","volume":"6","author":"Causin","year":"2016","journal-title":"J. Math. Ind."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0830","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.apm.2022.11.018","article-title":"New pathways for drug and gene delivery to the eye: a mathematical model","volume":"116","author":"Ferreira","year":"2023","journal-title":"Appl. Math. Model."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0835","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ces.2014.01.005","article-title":"Computational modeling of drug delivery to the posterior eye","volume":"108","author":"Kavousanakis","year":"2014","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0840","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mbs.2014.03.014","article-title":"Virtual pharmacokinetic model of human eye","volume":"253","author":"Kotha","year":"2014","journal-title":"Math. Biosci."},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0845","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10439-006-9238-x","article-title":"Protein transport to choroid and retina following periocular injection: theoretical and experimental study","volume":"35","author":"Mac Gabhann","year":"2007","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0850","series-title":"Computational Modelling of Aqueous Humor Dynamics and Drug Delivery for Intraocular Pressure Control in glaucoma","author":"Chowdhury","year":"2018"},{"issue":"7","key":"10.1016\/j.jconrel.2023.09.021_bb0855","first-page":"3473","article-title":"A new physiologically based pharmacokinetic (PBPK)-pharmacodynamic (PD) model for assessing efficacy of glaucoma medication","volume":"61","author":"Chowdhury","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0860","series-title":"Multiphysics-Based Computational Modeling of Ocular Therapeutics","author":"Chowdhury","year":"2022"},{"issue":"4","key":"10.1016\/j.jconrel.2023.09.021_bb0865","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-019-0334-x","article-title":"Application of mechanistic ocular absorption modeling and simulation to understand the impact of formulation properties on ophthalmic bioavailability in rabbits: a case study using dexamethasone suspension","volume":"21","author":"Le Merdy","year":"2019","journal-title":"AAPS J."},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0870","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11095-020-02965-y","article-title":"Ocular physiologically based pharmacokinetic modeling for ointment formulations","volume":"37","author":"Le Merdy","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0875","series-title":"Modeling of Drug Delivery to the Human Eye","author":"Mahathanthila","year":"2017"},{"issue":"12","key":"10.1016\/j.jconrel.2023.09.021_bb0880","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s11095-021-03141-6","article-title":"Ocular fluid mechanics and drug delivery: a review of mathematical and computational models","volume":"38","author":"Bhandari","year":"2021","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0885","first-page":"4","article-title":"Mathematical and numerical methods for modeling drug delivery to the posterior segment of the eye","volume":"1","author":"Causin","year":"2017","journal-title":"J. Ophthalm. Res. Ocul. Care"},{"issue":"8","key":"10.1016\/j.jconrel.2023.09.021_bb0890","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.drudis.2019.05.039","article-title":"Physiologically based ocular","volume":"24","author":"Missel","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0895","series-title":"General Considerations in Ocular Drug Delivery","first-page":"59","author":"Chastain","year":"2003"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.09.021_bb0900","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijpharm.2014.10.062","article-title":"High-throughput in vitro drug release and pharmacokinetic simulation as a tool for drug delivery system development: application to intravitreal ocular administration","volume":"477","author":"Sarkhel","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0905","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","article-title":"Intravitreal clearance and volume of distribution of compounds in rabbits: in silico prediction and pharmacokinetic simulations for drug development","volume":"95","author":"del Amo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0910","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/pharmaceutics11010009","article-title":"Pharmacokinetic simulations of intravitreal biologicals: aspects of drug delivery to the posterior and anterior segments","volume":"11","author":"Rimpela","year":"2019","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0915","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/jpet.120.000483","article-title":"Ocular pharmacokinetics of brimonidine drug delivery system in monkeys and translational dodeling for selection of dose and frequency in clinical trials","volume":"378","author":"Tamhane","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2023.09.021_bb0920","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/pharmaceutics13111862","article-title":"Compartmental and comsol multiphysics 3D modeling of drug diffusion to the vitreous following the administration of a sustained-release drug delivery system","volume":"13","author":"Dosmar","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0925","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-409X(01)00187-9","article-title":"Pharmacokinetic model for in vivo\/in vitro correlation of intravitreal drug delivery","volume":"52","author":"Tojo","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2023.09.021_bb0930","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2005.03.010","article-title":"Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant","volume":"105","author":"Park","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.021_bb0935","doi-asserted-by":"crossref","first-page":"131080","DOI":"10.1016\/j.matlet.2021.131080","article-title":"In silico model of bevacizumab sustained release from intravitreal administrated PLGA drug-loaded microspheres","volume":"307","author":"Heljak","year":"2022","journal-title":"Mater. Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.021_bb0940","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1023\/A:1022207026982","article-title":"Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor","volume":"20","author":"Stay","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0945","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mbs.2014.06.008","article-title":"Computational modeling of drug distribution in the posterior segment of the eye: effects of device variables and positions","volume":"255","author":"Jooybar","year":"2014","journal-title":"Math. Biosci."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0950","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1115\/1.4051785","article-title":"Analytical and computational modeling of sustained-release drug implants in the vitreous humor","volume":"143","author":"Khoobyar","year":"2021","journal-title":"J. Heat Transf."},{"key":"10.1016\/j.jconrel.2023.09.021_bb0955","doi-asserted-by":"crossref","first-page":"11052","DOI":"10.1016\/j.jbiomech.2022.111052","article-title":"Drug sustained release from degradable drug-loaded in-situ hydrogels in the posterior eye: a mechanistic model and analytical method","volume":"136","author":"Li","year":"2022","journal-title":"J. Biomech."},{"issue":"23\u201324","key":"10.1016\/j.jconrel.2023.09.021_bb0960","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.ijheatmasstransfer.2008.04.053","article-title":"Computational modeling of intravitreal drug delivery in the vitreous chamber with different vitreous substitutes","volume":"51","author":"Kathawate","year":"2008","journal-title":"Int. J. Heat Mass Transf."},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.021_bb0965","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1137\/17M1163165","article-title":"Toward a precision ophthalmology: targeting the retina","volume":"78","author":"Ferreira","year":"2018","journal-title":"SIAM J. Appl. Math."},{"issue":"10","key":"10.1016\/j.jconrel.2023.09.021_bb0970","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.camwa.2020.09.007","article-title":"Mathematical model for degradation and drug release from an intravitreal biodegradable implant","volume":"80","author":"Ferreira","year":"2020","journal-title":"Comput. Math. Appl."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:52:23Z","timestamp":1759164743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923006089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":194,"alternative-id":["S0168365923006089"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.021","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}